Specify a stock or a cryptocurrency in the search bar to get a summary
Sagimet Biosciences Inc. Series A Common Stock
SGMTSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Address: 155 Bovet Road, San Mateo, CA, United States, 94402
Analytics
WallStreet Target Price
32.6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SGMT
Dividend Analytics SGMT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SGMT
Stock Valuation SGMT
Financials SGMT
Results | 2019 | Dynamics |